enGene Holdings Inc.
NASDAQ:ENGN · NASDAQ Capital Market
-$0.02 today
Vol 0.89M · Avg 1.58M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ENGN · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$66.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.32, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $94.5M +146.6% | $38.3M +132.8% | $16.5M +6.4% | $15.5M +24.1% | $12.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $28.7M +19.6% | $24.0M +183.1% | $8.5M +159.8% | $3.3M +3.3% | $3.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $123.2M +97.7% | $62.3M +139.1% | $26.1M +34.1% | $19.4M +22.4% | $15.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $509.0K +57.6% | $323.0K +84.6% | $175.0K -26.5% | $238.0K -12.5% | $272.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$113.8M -118.7% | -$52.0M +45.1% | -$94.8M -316.0% | -$22.8M -25.5% | -$18.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$123.2M -97.7% | -$62.3M -139.1% | -$26.1M -34.1% | -$19.4M -22.4% | -$15.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $9.4M -9.5% | $10.4M +832.2% | $1.1M +765.9% | $129.0K +416.0% | $25.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.0M +7.0% | $2.8M -43.5% | $5.0M +248.1% | $1.4M -71.7% | $5.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $5.9M -17.8% | $7.1M +109.7% | -$73.8M -1373.0% | -$5.0M +33.8% | -$7.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$117.3M -112.7% | -$55.2M +44.8% | -$99.9M -308.8% | -$24.4M -4.3% | -$23.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 +100.0% | -$19.0K -211.8% | $17.0K -22.7% | $22.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$117.3M -112.7% | -$55.1M +44.8% | -$99.9M -308.5% | -$24.5M -4.4% | -$23.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -56.8% | -$1 +65.6% | -$4 -223257.9% | $0 +113.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -56.8% | -$1 +65.6% | -$4 -223257.9% | $0 +113.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $51.1M +14.5% | $44.6M +89.5% | $23.6M +49.0% | $15.8M +0.0% | $15.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $51.1M +14.5% | $44.6M +89.5% | $23.6M +49.0% | $15.8M +0.0% | $15.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alto Neuroscience, Inc.
NYSE:ANRO
$795.58M
Annexon, Inc.
NASDAQ:ANNX
$591.40M
DBV Technologies S.A.
NASDAQ:DBVT
$379.28M
Amarin Corporation plc
NASDAQ:AMRN
$335.06M
Silence Therapeutics plc
NASDAQ:SLN
$321.13M
Cellectis S.A.
NASDAQ:CLLS
$308.78M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$307.08M
AC Immune S.A.
NASDAQ:ACIU
$243.75M
Altimmune, Inc.
NASDAQ:ALT
$241.87M
Korro Bio, Inc.
NASDAQ:KRRO
$127.35M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ENGN generate?
enGene Holdings Inc. (ENGN) reported $0.00 of revenue in fiscal 2025.
Is ENGN profitable?
enGene Holdings Inc. (ENGN) reported -$117,302,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.